Loading clinical trials...
Loading clinical trials...
TEAM-Trial: Targeting Epigenetic Therapy Resistance in AML With Bortezomib: A Multi-centre Matched Threshold Crossing Phase II Approach
Conditions
Interventions
Bortezomib
Gemtuzumab Ozogamicin
Locations
1
Germany
University Hospital Heidelberg, Internal Medicine V
Heidelberg, Baden-Wurttemberg, Germany
Start Date
October 22, 2019
Primary Completion Date
February 28, 2023
Completion Date
March 24, 2023
Last Updated
March 27, 2023
NCT06285890
NCT06220162
NCT04065399
NCT06994676
NCT06484062
NCT04628026
Lead Sponsor
University Hospital Heidelberg
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions